Drug intelligence / Profile preview

TQB3558

Development stage: Phase 1
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

TQB3558 is an orally available small molecule inhibitor of tropomyosin receptor kinases (Trk), including TrkA, TrkB, and TrkC. It is being developed for its potential antineoplastic activity and as a treatment for cancer pain. By inhibiting the activity of these kinases, which are involved in the growth and survival of certain cancer cells as well as pain signaling pathways, TQB3558 may suppress tumor progression and alleviate cancer-related pain. The drug is under development by Chia Tai Tianqing Pharmaceutical Group.

Other names: TRK inhibitor TQB3558

Targets

NTRK1 (Tropomyosin-related receptor kinase A)NTRK3 (Tropomyosin receptor kinase C)NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on TQB3558.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQB3558.

Explore the full profile